Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
Epistemonikos ID: 8223a4e4c3f9471daee79262ce2ea474385b2f9f
First added on: May 21, 2024